In line with these results, clinical trials are testing the anti-PD-1 antibody pembrolizumab combined with demethylation agents to further examine the potential of sensitizing NSCLC patients to PD-1/PD-L1 axis immunotherapy [46]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.